REQUEST PER XEIDESSING F ABAND	DONED APPLICATION UNDER 37 CFR 1.14(8)
	In re Application of
·	Lobb et al.
•	Application Number Fied
	00 0 10,00
	
	99 EC /2
Assistant Commissioner for Patents	Paper No. 7
Washington, DC 20231	ED 600/29
LIBER ARANIX MPC BECHESTON WINGS	is: (CHECK ONE)
(A) referred to in United States Patent !	Number 5932 219 column
appacation No	coen to public inspection as set forth in 37 CFR 1.11, i.e., filed of
(C) an application that daims the bene inspection, i.e., Application No	est of the sung cate of an application that is open to public
(D) an application in which the application to the public.	ant has filed an authorization to lay open the complete
Please direct any correspondence concer	ming this request to the following address:
Janchay Cheeyava	8 11 99
	i i
SOMCHAY CHIN	YAVONG- FOR PTO USE ONLY
Typed or printed name	Approved by:(initials)
	Unit:



United States Patent [19]

Lobb et al.

[11] Patent Number:

5,932,214

[45] Date of Patent:

Aug. 3, 1999

[54] TREATMENT FOR INFLAMMATORY BOWEL DISEASE WITH VLA-4 BLOCKERS

[75] Inventors: Roy R. Lobb, Westwood; Linda C. Burkly, West Newton, both of Mass.

[73] Assignee: Biogen, Inc., Cambridge, Mass.

[21] Appl. No.: **08/950,660**

[22] Filed: Oct. 15, 1997

Related U.S. Application Data

[62ntinuation of application No. 08/456,124, May 31, 1995., abandoned, which is a continuation-in-part of application No. 08/373,857, Jan. 18, 1995., abandoned, which is a continuation-in-part of application No. 08/284,603, Aug. 11, 1994., abandoned, which is a continuation-in-part of application No. 07/835,139, filed as application No. PCT/US93/00924, Feb. 2, 1993., abandoned

[51]	Int. Cl. ⁶	A61K 39/395 ; A61K 38/17
[52]	U.S. Cl	424/144.1; 424/130.1;
		34.1; 424/136.1; 424/141.1;
	424/143.4; 42	24/153.1; 424/154.1; 514/2;
	514/8; 514/885; 530/	350; 530/387.1; 530/387.3;
	530/388.1; 530/388	3.2; 530/388.22; 530/388.7;
		530/388.73; 530/388.75
[58]	Field of Search	424/130.1, 133.1,
	404/141 1 152 1	. 514D 0, 520/250 200 1

[56]

References Cited

U.S. PATENT DOCUMENTS

4,816,397	3/1989	Boss et al 435/68
4,833,092	5/1989	Geysen 436/501
		Capon et al
		Hession et al
5,730,978	3/1998	Wayner .

FOREIGN PATENT DOCUMENTS

0 314 863	5/1989	European Pat. Off.
0 330 506	9/1989	European Pat. Off.
0 333 517	9/1989	European Pat. Off.
0 346 078	12/1989	European Pat. Off.
WO 90/03400	4/1990	WIPO.
WO 90/13300	11/1990	WIPO.
9103252	3/1991	WIPO .
WO 92/00751	1/1992	WIPO.
WO 93/13798	1/1992	WIPO.
WO 95/19790	7/1995	WIPO .

OTHER PUBLICATIONS

Jakubowski, et al. "Vascular Cell Adhesion Molecule (VCAM)-Ig Fusion Protein Defines Distinct Affinity States of the Very Late Antigen-4 (VLA-4) Receptor" Cell Adhesion and Communication 3:131-142 (1995).

Brown, Jr., P. et al., "Anti-Tac-H, a Humanized Antibody to the Interleukin 2 Receptor, Prolongs Primate Cardiac Allograft Survival" *Proc. Natl. Acad. Sci. USA* 88:2663-2667 (1990).

Burkly, L. et al., "Signaling by Vascular Cell Adhesion Molecule-1 (VCAM-1) Through VLA-4 Promotes CD3-dependent T Cell Proliferation" Eur. J. Immunol. 21:2871-2875 (1991).

Clackson, T. et al., "Making Antibody Fragments Using Phage Display Libraries" Nature 352:624-628 (1991).

Co, M.S. et al., "Humanized Antibodies for Antiviral Therapy" Proc. Natl. Acad. Sci. USA 88:2869-2873 (1990).

Damle, N. et al., "Vascular Cell Adhesion Molecule 1 Induces T-cell Antigen Receptor-dependent Activation of CD4⁺ T Lymphocytes" *Proc. Natl. Acad. Sci. USA* 88:6403-6407 (1991).

Devlin, J. et al., "Random Peptide Libraries: A Source of Specific Protein Binding Molecules" *Science* 249:400-406 (1990).

Dobrina, A. et al., "Mechanisms of Eosinophil Adherence to Cultured Vascular Endothelial Cells" J. Clin. Invest. 88:20-26 (1991).

Elices, M.J. et al., "VCAM-1 on Activated Endothelium Interacts with the Leukocyte Integrin VLA-4 at a Site Distinct from the VLA-4/Fibronectin Binding Site" Cell 60:577-584 (1990).

Freedman, A. et al., "Adhesion of Human B Cells to Germinal Centers in Vitro Involves VLA-4 and INCAM-110" Science 249:1030-1033 (1990).

Harris, W.J. and S. Emery, "Therapeutic antibodies—the coming of age" TIBTECH 11: 42-44 (1993).

Hemler, M. E. et al., "Characterization of the Cell Surface Heterodimer VLA-4 and Related Peptides" J. Biol. Chem. 262(24):11478-11485 (1987).

Holzmann, B. and I.L. Weissman, "Integrin Molecules Involved in Lymphocyte Homing to Peyer's Patches" *Immunolical Reviews* 0(108):45-61 (1989).

Podolsky, D.K. et al., "Colonic Mucin Composition in Primates Selective Alterations Associated with Spontaneous Colitis in the Cotton-top Tamarin" *Gastroent*. 88:20-25 (1985).

Podolsky, D.K. et al., "Spontaneous Colitis In Cotton-Top Tamarins: Histologic, Clinical and Biochemical Features of an Animal Model of Chromic Colitis" Digestive Diseases and Sciences 30(4):396 (A-32) (1985).

Pulido, R. et al., "Functional Evidence for Three Distinct and Independently Inhibitable Adhesion Activities Mediated by the Human Integrin VLA-4" J. Biol. Chem. 266(16):10241-10245 (1991).

Rice, G.E. et al., "Vascular and Nonvascular Expression of INCAM-110", Am. J. Pathology 138(2):385-393 (1991).

Riechmann, L. et al., "Reshaping Human Antibodies for Therapy" Nature 332:323-327 (1988).

(List continued on next page.)

Primary Examiner—Christina Y. Chan Assistant Examiner—Phillip Gambel Attorney, Agent, or Firm—Fish & Richardson P.C.

[57] ABSTRACT

A method for the treatment of inflammatory bowel disease (IBD) is disclosed. The method comprises administration of an antibody, polypeptide or other molecule recognizing VLA-4, a surface molecule expressed on most types of white blood cells and involved in leukocyte adhesion to endothelium and other tissus in the gut.

15 Claims, 8 Drawing Sheets